The following video is part of our "Motley Fool Conversations" series, in which analyst John Reeves and advisor David Meier discuss topics across the investing world.
David took a closer look at Solazyme recently, and still feels it is a possible future recommendation for the 10-Bagger real-money portfolio. The company has been tackling both its demand and its supply problem at the same time. Biofuel companies, of course, carry big risks, and Solazyme is no different in this regard. But David likes the way Solazyme is attacking the problem by going after high-end products like food and health products before going heavy into fuels. That's why the company is on David and John's watchlist.
Growth investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.
At the time thisarticle was published David Meierhas no positions in the stocks mentioned above.John Reeveshas no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above.Motley Fool newsletter services recommendChevron and Unilever. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.